Replies to post #7212 on The Rising Influence of Rising Affluence

[DewDiligence]

MNTA has multiple shots on goal—generic Copaxone, FoB program, potential Lovenox-patent damages—and you’re paying almost nothing for them at the current valuation. Moreover, MNTA has ample cash* to last a long time, so you don’t have to worry about dilution.

*$344M as of 3/31/13 (including $20M of restricted cash).